Literature DB >> 25079592

Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis.

Julie Autmizguine1, Michael Cohen-Wolkowiez, Norman Ilowite.   

Abstract

Entities:  

Keywords:  interleukin-1 inhibitor; pediatrics; population pharmacokinetics; systemic juvenile idiopathic arthritis

Mesh：

Substances：

Year:  2014        PMID： 25079592      PMCID： PMC4276471          DOI： 10.1002/jcph.372

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  17 in total

Review 1.  Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome.

Authors:  Patricia Woo
Journal:  Nat Clin Pract Rheumatol       Date:  2006-01

2.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

3.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

4.  Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing?

Authors:  L S Peterson; T Mason; A M Nelson; W M O'Fallon; S E Gabriel
Journal:  Arthritis Rheum       Date:  1996-08

5.  Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.

Authors:  Deborah L Mortensen; Patricia A Walicke; Xiaolin Wang; Paul Kwon; Peter Kuebler; Alice B Gottlieb; James G Krueger; Craig Leonardi; Bruce Miller; Amita Joshi
Journal:  J Clin Pharmacol       Date:  2005-03       Impact factor: 3.126

6.  Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study.

Authors:  B A Gäre; A Fasth
Journal:  Pediatrics       Date:  1992-12       Impact factor: 7.124

Review 7.  Health outcomes in pediatric rheumatic diseases.

Authors:  Ciaran M Duffy
Journal:  Curr Opin Rheumatol       Date:  2004-03       Impact factor: 5.006

8.  Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Edward H Giannini; Andreas O Reiff; Yukiko Kimura; Suzanne Li; Philip J Hashkes; Carol A Wallace; Karen B Onel; Dirk Foell; Richard Wu; Stephanie Biedermann; Jennifer D Hamilton; Allen R Radin
Journal:  Arthritis Rheum       Date:  2013-09

9.  Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.

Authors:  Norman T Ilowite; Kristi Prather; Yuliya Lokhnygina; Laura E Schanberg; Melissa Elder; Diana Milojevic; James W Verbsky; Steven J Spalding; Yukiko Kimura; Lisa F Imundo; Marilynn G Punaro; David D Sherry; Stacey E Tarvin; Lawrence S Zemel; James D Birmingham; Beth S Gottlieb; Michael L Miller; Kathleen O'Neil; Natasha M Ruth; Carol A Wallace; Nora G Singer; Christy I Sandborg
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

10.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.

Authors:  Virginia Pascual; Florence Allantaz; Edsel Arce; Marilynn Punaro; Jacques Banchereau
Journal:  J Exp Med       Date:  2005-04-25       Impact factor: 14.307
View more
  5 in total

1.  Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.

Authors:  Megha Garg; Adriana A de Jesus; Dawn Chapelle; Paul Dancey; Ronit Herzog; Rafael Rivas-Chacon; Theresa L Wampler Muskardin; Ann Reed; James C Reynolds; Raphaela Goldbach-Mansky; Gina A Montealegre Sanchez
Journal:  JCI Insight       Date:  2017-08-17

Review 2.  Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.

Authors:  Bryan Q Abadie; Paul C Cremer
Journal:  BioDrugs       Date:  2022-05-31       Impact factor: 7.744

Review 3.  The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets.

Authors:  Tao Liang; Yang Zhang; Suyuan Wu; Qingjie Chen; Lin Wang
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

Review 4.  Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.

Authors:  Laura A Wang; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Adv Pediatr       Date:  2016-08

Review 5.  Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.

Authors:  Alessandra Soriano; Marco Soriano; Gerard Espinosa; Raffaele Manna; Giacomo Emmi; Luca Cantarini; José Hernández-Rodríguez
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.